Your browser doesn't support javascript.
loading
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).
Kates, Max; Chu, Xiangying; Hahn, Noah; Pietzak, Eugene; Smith, Angela; Shevrin, Daniel H; Crispen, Paul; Williams, Stephen B; Daneshmand, Siamak; Packiam, Vignesh T; Porten, Sima; Westerman, Mary E; Wagner, Lynne I; Carducci, Michael.
Afiliación
  • Kates M; Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA. Electronic address: mkates@jhmi.edu.
  • Chu X; Department of Biostatistics, School of Medicine, Harvard University, Boston, MA, USA.
  • Hahn N; Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.
  • Pietzak E; Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Smith A; Department of Urology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
  • Shevrin DH; Northshore Medical Group, Glenview, IL, USA.
  • Crispen P; Department of Urology, University of Florida School of Medicine, Gainesville, FL, USA.
  • Williams SB; Division of Urology, University of Texas Medical Branch, Galveston, TX, USA.
  • Daneshmand S; Catherine and Joseph Aresty Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
  • Packiam VT; Department of Urology, University of Iowa, Iowa City, IA, USA.
  • Porten S; Department of Urology, UCSF School of Medicine, San Francisco, CA, USA.
  • Westerman ME; Department of Urology, LSU Health Science Center, New Orleans, LA, USA.
  • Wagner LI; Department of Social Sciences and Health Policy, School of Medicine, Wake Forest University, Winston-Salem, NC, USA.
  • Carducci M; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Eur Urol Focus ; 9(4): 561-563, 2023 07.
Article en En | MEDLINE | ID: mdl-37422371
ABSTRACT
EA8212 BRIDGE is a phase 3 randomized trial comparing BCG vs GemDoce for BCG naïve high-risk non-muscle-invasive bladder cancer. This article provides an explanation for the rationale of the clinical trial and details the study design.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Neoplasias Vesicales sin Invasión Muscular Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Eur Urol Focus Año: 2023 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Neoplasias Vesicales sin Invasión Muscular Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Eur Urol Focus Año: 2023 Tipo del documento: Article